The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

About

Terms

 

 
 

Sitaxsentan (ICOS-Texas Biotechnology).

ICOS-Texas Biotechnology is developing the endothelin A (ETA) receptor antagonist, sitaxsentan, for the potential treatment of pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease and subarachnoid hemorrhage [205713], [302200]. The compound is in phase IIa trials as an iv formulation for CHF and has completed phase I safety trials as an oral formulation [272071]. Phase II/III trials for pulmonary hypertension are planned for the first quarter of 2001 [3945711]. In June 2000, ICOS and Texas Biotechnology established a joint venture to develop and commercialize endothelin antagonists [370007]. US-05591761 was issued to Texas in January 1997, covering TBC-11251 and several related isomers [2309301.[1]

References

  1. Sitaxsentan (ICOS-Texas Biotechnology). Wu-Wong, J.R. Current opinion in investigational drugs (London, England : 2000) (2001) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
 
WikiGenes - Universities